Invitae's Breast Cancer Tests Get New Medicare Reimbursement Code

Apr 19, 2016

|

NEW YORK (GenomeWeb) – Invitae announced today that its multi-gene tests for hereditary breast cancer-related disorders will now be reimbursed by the Centers for Medicare and Medicaid Services (CMS) under a new molecular diagnostics current procedure terminology (CPT) code.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Mysterious Third Group

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

This Week in Science

In Science this week: reduction in bee phylogenetic diversity, and more.

In the Past

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

New Bases, New Drugs

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Featured White Papers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

DNA Quantification and Normalization with Promega QuantiFluor Dyes on the Fluent Laboratory Automation Solution

Nucleic Acid Quantification and Normalization by UV Measurement on the Fluent Laboratory Automation Solution

qPCR Setup with the Kapa SYBR FAST qPCR Kit on the Fluent Automation Workstation

Jan

30

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Main menu